Formulary Watch April 2024
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
FDA approves Simtriyo, the first triple reuptake inhibitor for ADHD
2
CMS sets the 2027 Part D bid amount at $296.05, will end premium subsidy program
3
Long-acting Cabenuva beats daily oral HIV therapy in adolescents | AIDS 2026
4
Five drugs stand out for antipsychotic-induced weight gain, study finds
5